图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
真核基因表达评论综述™
影响因子: 1.841 5年影响因子: 1.927 SJR: 0.649 SNIP: 0.516 CiteScore™: 1.96

ISSN 打印: 1045-4403
ISSN 在线: 2162-6502

真核基因表达评论综述™

DOI: 10.1615/CritRevEukaryotGeneExpr.2014011495
pages 281-286

Ductal Carcinoma In Situ: A Brief Review of Treatment Variation and Impacts on Patients and Society

Christine Vatovec
Rubenstein School of Environment and Natural Resources & College of Medicine, Vermont Cancer Center, University of Vermont, Burlington, Vermont
Mujde Z. Erten
Department of Surgery, College of Medicine, Vermont Cancer Center, University of Vermont, Burlington, Vermont; Global Health Economics Unit of the Vermont Center for Clinical and Translational Science, University of Vermont, Burlington, Vermont
Jane Kolodinsky
Department of Community Development and Applied Economics, University of Vermont, Burlington, Vermont
Phil Brown
Department of Sociology and Anthropology, Department of Health Sciences, Northeastern University, Boston, Massachusetts
Marie Wood
Department of Medicine, College of Medicine, Vermont Cancer Center, University of Vermont, Burlington, Vermont
Ted James
Department of Surgery, College of Medicine, Vermont Cancer Center, University of Vermont, Burlington, Vermont
Brian L. Sprague
Department of Surgery, College of Medicine, Vermont Cancer Center, University of Vermont, Burlington, Vermont

ABSTRACT

Nearly 20% of all breast cancer cases are ductal carcinoma in situ (DCIS), with over 60,000 cases diagnosed each year. Many of these cases would never cause clinical symptoms or threaten the life of the woman; however, it is currently impossible to distinguish which lesions will progress to invasive disease from those that will not. DCIS is generally associated with an excellent prognosis regardless of the treatment pathway, but there is variation in treatment aggressiveness that seems to exceed the medical uncertainty associated with DCIS management. Therefore, it would seem that a significant proportion of women with DCIS receive more extensive treatment than is needed. This overtreatment of DCIS is a growing concern among the breast cancer community and has implications for both the patient (via adverse treatment-related effects, as well as out-of-pocket costs) and society (via economic costs and the public health and environmental harm resulting from health care delivery). This article discusses DCIS treatment pathways and their implications for patients and society and calls for further research to examine the factors that are leading to such wide variation in treatment decisions.


Articles with similar content:

Optimizing Outcome in the Injured Worker with Low Back Pain
Critical Reviews™ in Physical and Rehabilitation Medicine, Vol.11, 1999, issue 2
Scott F. Nadler, Todd P. Stitik, Gerard A. Malanga
The Effect of Exercise Training on Breast Cancer Patients: A Review
Critical Reviews™ in Physical and Rehabilitation Medicine, Vol.31, 2019, issue 3
Lily-Thao Nguyen, Vivek Patel
Human Prostate Carcinogenesis
Critical Reviews™ in Oncogenesis, Vol.8, 1997, issue 4
Hsiang-fu Kung, Johng S. Rhim
Assistive Technologies for Cognitive Disabilities
Critical Reviews™ in Physical and Rehabilitation Medicine, Vol.17, 2005, issue 3
Maria Schulthesis, Marcia J. Scherer, Ned Kirsch, Tessa Hart
Need for an Ethical Framework for Testing for Systemic Diseases in Dental Clinics
Ethics in Biology, Engineering and Medicine: An International Journal, Vol.2, 2011, issue 2
Amit Chattopadhyay, Marushka Leanne Silveira